Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg orally once a day in the morning.

Group 2 (STE) included 32 patients receiving tomato fruit extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally once a day in the morning.

Hypertension,Essential

Obesity

Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg in the morning

acetylsalicylic acid

Group 2 (STE) included 32 patients receiving standardized tomato extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally in the morning

Tomato Fruit Extract

Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects

Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects at High Estimated Cardiovascular Risk

The platelet inhibition after STE and ASA therapy (VerifyNow Aspirin for ASA and STE Groups and VerifyNow P2Y12 for STE Group only) The platelet reactivity measurements will be performed using the VerifyNow Tests (Accumetrics Inc., USA) method.

The reduction in office BP (measured three times in standard conditions) and in 24-hour ABPM parameters

Beata Krasinska

Principal Investigator

Atherothrombosis

Aspirin

Triflusal

Atherothrombosis Research Centre / Laboratory of Biochemistry, University of Ioannina

ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)

Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events

Number of participants who suffer from the primary efficacy end point which is the composite of death from vascular causes, myocardial infarction(MI), or stroke during the twelve month treatment period

Number of participants who suffer from the rate of bleeding events as defined by Bleeding Academic Research Consortium (BARC) criteria during the twelve month treatment period

Number of participants who suffer from the secondary efficacy end point which is the composite of death from any cause, MI, or stroke during the twelve month treatment period

Number of participants who suffer from the secondary safety end points which are hypersensitivity or intolerance to study drugs during the twelve month treatment period

Alexandros Tselepis

Professor of Biochemistry and Clinical Chemistry

University of Ioannina

Tablet Tadalafil 20 mg every alternate day

Lung Diseases, Interstitial

Tab. Tadalafil 20 mg every other day for 6 months

Tadalafil

Shape , size, color and odor matched Tab. of inert material every other day for 6 months

Placebo

SGPGIMS

A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma

A Double Blind Randomized Control Trial of Tadalafil in Interstitial Lung Disease of Scleroderma

To assess the change in FVC (expressed as a percentage of the predicted value) from baseline values at the end of 6 months

To assess the improvement in dyspnoea (as measured by Mehler dyspnoea index) at the end of 6 month

To assess improvement in 6 min walk test at the end of 6 months

To assess the change in DLCO from baseline values at the end of 6 months

To assess the change in total lung capacity from baseline values at the end of 6 months

To assess the change in the disability index of the Health Assessment Questionnaire (S HAQ) at 6 months from baseline

To assess the change in the Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36) from baseline to end of 6 months

Vikas Agarwal

Additional Professor

Sanjay Gandhi Postgraduate Institute of Medical Sciences

Hypertension

Blood pressure lowering therapy except ARB

guanosine/infarkt

Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects

ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)

A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma

A Trial of Telmisartan Prevention of Cardiovascular Disease

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen